Black Patients’ Access To ‘Revolutionary’ Treatments Stymied By Stark Under-Representation In Clinical Trials

There's a regulatory reluctance to impose diversity requirements for drug trials, but that's left a gaping disparity around who has access to new and life-changing cancer drugs. In other public health news: Alzheimer's, vaping, marijuana drugs, diabetes, DNA, obesity, and more.

from Kaiser Health News https://ift.tt/2NSziKK